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The extracellular amyloid deposits which disrupt tissue architecture are unequivocally pathogenic 
and a major cause of organ dysfunction in all forms of systemic amyloidosis [1].  Systemic amyloid 
deposits generally evoke little or no local or systemic inflammatory response.  In contrast to the 
usual rapid spontaneous removal of extracellular debris, amyloid deposits regress slowly if at all, 
even when the abundance of amyloid fibril precursor proteins is reduced [1].  Swift therapeutic 
reduction of amyloid load is therefore highly desirable.  Antibodies to serum amyloid P component 
(SAP) achieve this objective by targeting the SAP which is universally present in all human amyloid 
deposits.  It is obviously impossible to administer anti-SAP antibodies alone because the circulating 
SAP in the plasma would form pathogenic immune complexes and also consume the antibody before 
it could reach SAP in the amyloid deposits.  However the drug CPHPC (hexanoyl bis(D-proline), 
safely and potently depletes circulating SAP [2] but leaves some SAP in the amyloid deposits [3]  
to serve as the antigen target for the therapeutic antibody.  Prior administration of CPHPC thus 
makes it feasible to administer anti-SAP antibody which can bind to the SAP coated amyloid.  In 
murine experimental models, 
amyloid clearance by anti-SAP 
depends on classical complement 
pathway activation and 
macrophages [4].  It is mediated 
by antibody binding to amyloid-
associated SAP, leading to 
complement activation, C3 
deposition on the amyloid, 
attraction and then engagement of 
macrophages that rapidly fuse to 
form multinucleated giant cells 
[4].  These cells have a unique 
phenotype, which we have 
recently characterised [5], and 
which specifically equips them to surround, engulf and destroy large complement opsonised objects. 
 
The obligate therapeutic partnership of CPHPC and anti-SAP antibody is being developed by 
GlaxoSmithKline and has been safe and generally well tolerated in patients with systemic AL, AA, 
AApoAI and AFib amyloidosis [6, 7].  Anti-SAP infusion triggered immediately increased 
production of IL-6, but not TNFα.  Early acute-phase responses of CRP and SAA were followed by 
substantial plasma C3 depletion [6, 7].  Variable infusion reaction were abrogated by hydrocortisone 
and antihistamine premedication but most subjects receiving higher antibody doses developed skin 
rashes, though only one was serious and it responded to oral prednisone [6, 7].  Importantly, no 
increased dysfunction was observed in any amyloidotic or other organs, including the kidney [6, 7].  
Amyloid clearance was unequivocally confirmed by reduction of extracellular volume in 
amyloidotic organs, reduction of amyloid load measured by SAP scintigraphy and decreased liver 
stiffness in patients with hepatic amyloidosis [6, 7].  Crucially, reduction of amyloid load was 
associated with improved organ function, especially in the liver [6, 7].  Repeat antibody doses 
progressively reduced amyloid load with corresponding functional improvement [6, 7]. 
Conclusion. Anti-SAP antibody triggers rapid non-tissue damaging amyloid clearance from the 
extracellular space, a process which is otherwise very slow or absent.  Cardiac involvement is the 
major cause of morbidity and mortality in systemic amyloidosis and a phase 2 trial of repeat CPHPC 
plus anti-SAP dosing in patients with cardiac AL and ATTR amyloidosis is now planned. 
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